Suppr超能文献

产甲酸草酸杆菌及其在人体肠道草酸代谢中的作用。

Oxalobacter formigenes and its role in oxalate metabolism in the human gut.

作者信息

Stewart Colin S, Duncan Sylvia H, Cave David R

机构信息

Division of Gut Microbiology and Immunology, Rowett Research Institute, Bucksburn, Aberdeen, UK.

出版信息

FEMS Microbiol Lett. 2004 Jan 15;230(1):1-7. doi: 10.1016/S0378-1097(03)00864-4.

Abstract

Oxalate is ingested in a wide range of animal feeds and human foods and beverages and is formed endogenously as a waste product of metabolism. Bacterial, rather than host, enzymes are required for the intestinal degradation of oxalate in man and mammals. The bacterium primarily responsible is the strict anaerobe Oxalobacter formigenes. In humans, this organism is found in the colon. O. formigenes has an obligate requirement for oxalate as a source of energy and cell carbon. In O. formigenes, the proton motive force for energy conservation is generated by the electrogenic antiport of oxalate(2-) and formate(1-) by the oxalate-formate exchanger, OxlT. The coupling of oxalate-formate exchange to the reductive decarboxylation of oxalyl CoA forms an 'indirect' proton pump. Oxalate is voided in the urine and the loss of O. formigenes may be accompanied by elevated concentrations of urinary oxalate, increasing the risk of recurrent calcium oxalate kidney stone formation. Links between the occurrence of nephrolithiasis and the presence of Oxalobacter have led to the suggestion that antibiotic therapy may contribute to the loss of this organism from the colonic microbiota. Studies in animals and human volunteers have indicated that, when administered therapeutically, O. formigenes can establish in the gut and reduce the urinary oxalate concentration following an oxalate load, hence reducing the likely incidence of calcium oxalate kidney stone formation. The findings to date suggest that anaerobic, colonic bacteria such as O. formigenes, that are able to degrade toxic compounds in the gut, may, in future, find application for therapeutic use, with substantial benefit for human health and well-being.

摘要

草酸盐存在于多种动物饲料、人类食品和饮料中,并且作为代谢废物在体内内源性形成。在人类和哺乳动物中,肠道内草酸盐的降解需要细菌而非宿主的酶。主要负责的细菌是严格厌氧菌产甲酸草酸杆菌。在人类中,这种微生物存在于结肠中。产甲酸草酸杆菌对草酸盐有绝对需求,将其作为能量和细胞碳源。在产甲酸草酸杆菌中,用于能量保存的质子动力是由草酸根离子(2-)和甲酸根离子(1-)通过草酸-甲酸交换体OxlT进行电中性反向转运产生的。草酸-甲酸交换与草酰辅酶A的还原脱羧偶联形成一个“间接”质子泵。草酸盐通过尿液排出,产甲酸草酸杆菌的缺失可能伴随着尿草酸浓度升高,增加复发性草酸钙肾结石形成的风险。肾结石的发生与产甲酸草酸杆菌的存在之间的联系表明,抗生素治疗可能导致这种微生物从结肠微生物群中缺失。对动物和人类志愿者的研究表明,当进行治疗性给药时,产甲酸草酸杆菌可以在肠道中定殖,并在摄入草酸盐后降低尿草酸浓度,从而降低草酸钙肾结石形成的可能性。迄今为止的研究结果表明,像产甲酸草酸杆菌这样能够在肠道中降解有毒化合物的厌氧结肠细菌,未来可能会在治疗中得到应用,对人类健康和福祉有很大益处。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验